Revolutionizing in vivo therapy with CRISPR/Cas genome editing: breakthroughs, opportunities and challenges
Genome editing using the CRISPR/Cas system has revolutionized the field of genetic engineering, offering unprecedented opportunities for therapeutic applications in vivo. Despite the numerous ongoing clinical trials focusing on ex vivo genome editing, recent studies emphasize the therapeutic promise...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Genome Editing |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fgeed.2024.1342193/full |
| _version_ | 1797337221147131904 |
|---|---|
| author | Arturo Macarrón Palacios Patrick Korus Bodo G. C. Wilkens Najmeh Heshmatpour Sarita R. Patnaik |
| author_facet | Arturo Macarrón Palacios Patrick Korus Bodo G. C. Wilkens Najmeh Heshmatpour Sarita R. Patnaik |
| author_sort | Arturo Macarrón Palacios |
| collection | DOAJ |
| description | Genome editing using the CRISPR/Cas system has revolutionized the field of genetic engineering, offering unprecedented opportunities for therapeutic applications in vivo. Despite the numerous ongoing clinical trials focusing on ex vivo genome editing, recent studies emphasize the therapeutic promise of in vivo gene editing using CRISPR/Cas technology. However, it is worth noting that the complete attainment of the inherent capabilities of in vivo therapy in humans is yet to be accomplished. Before the full realization of in vivo therapeutic potential, it is crucial to achieve enhanced specificity in selectively targeting defective cells while minimizing harm to healthy cells. This review examines emerging studies, focusing on CRISPR/Cas-based pre-clinical and clinical trials for innovative therapeutic approaches for a wide range of diseases. Furthermore, we emphasize targeting cancer-specific sequences target in genes associated with tumors, shedding light on the diverse strategies employed in cancer treatment. We highlight the various challenges associated with in vivo CRISPR/Cas-based cancer therapy and explore their prospective clinical translatability and the strategies employed to overcome these obstacles. |
| first_indexed | 2024-03-08T09:07:19Z |
| format | Article |
| id | doaj.art-5ec27129f17e40079967c9cee76a10d7 |
| institution | Directory Open Access Journal |
| issn | 2673-3439 |
| language | English |
| last_indexed | 2024-03-08T09:07:19Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genome Editing |
| spelling | doaj.art-5ec27129f17e40079967c9cee76a10d72024-02-01T04:29:14ZengFrontiers Media S.A.Frontiers in Genome Editing2673-34392024-02-01610.3389/fgeed.2024.13421931342193Revolutionizing in vivo therapy with CRISPR/Cas genome editing: breakthroughs, opportunities and challengesArturo Macarrón PalaciosPatrick KorusBodo G. C. WilkensNajmeh HeshmatpourSarita R. PatnaikGenome editing using the CRISPR/Cas system has revolutionized the field of genetic engineering, offering unprecedented opportunities for therapeutic applications in vivo. Despite the numerous ongoing clinical trials focusing on ex vivo genome editing, recent studies emphasize the therapeutic promise of in vivo gene editing using CRISPR/Cas technology. However, it is worth noting that the complete attainment of the inherent capabilities of in vivo therapy in humans is yet to be accomplished. Before the full realization of in vivo therapeutic potential, it is crucial to achieve enhanced specificity in selectively targeting defective cells while minimizing harm to healthy cells. This review examines emerging studies, focusing on CRISPR/Cas-based pre-clinical and clinical trials for innovative therapeutic approaches for a wide range of diseases. Furthermore, we emphasize targeting cancer-specific sequences target in genes associated with tumors, shedding light on the diverse strategies employed in cancer treatment. We highlight the various challenges associated with in vivo CRISPR/Cas-based cancer therapy and explore their prospective clinical translatability and the strategies employed to overcome these obstacles.https://www.frontiersin.org/articles/10.3389/fgeed.2024.1342193/fullCRISPR/Casgenome editingcancerpersonalized therapiesprecision medicinein vivo trials |
| spellingShingle | Arturo Macarrón Palacios Patrick Korus Bodo G. C. Wilkens Najmeh Heshmatpour Sarita R. Patnaik Revolutionizing in vivo therapy with CRISPR/Cas genome editing: breakthroughs, opportunities and challenges Frontiers in Genome Editing CRISPR/Cas genome editing cancer personalized therapies precision medicine in vivo trials |
| title | Revolutionizing in vivo therapy with CRISPR/Cas genome editing: breakthroughs, opportunities and challenges |
| title_full | Revolutionizing in vivo therapy with CRISPR/Cas genome editing: breakthroughs, opportunities and challenges |
| title_fullStr | Revolutionizing in vivo therapy with CRISPR/Cas genome editing: breakthroughs, opportunities and challenges |
| title_full_unstemmed | Revolutionizing in vivo therapy with CRISPR/Cas genome editing: breakthroughs, opportunities and challenges |
| title_short | Revolutionizing in vivo therapy with CRISPR/Cas genome editing: breakthroughs, opportunities and challenges |
| title_sort | revolutionizing in vivo therapy with crispr cas genome editing breakthroughs opportunities and challenges |
| topic | CRISPR/Cas genome editing cancer personalized therapies precision medicine in vivo trials |
| url | https://www.frontiersin.org/articles/10.3389/fgeed.2024.1342193/full |
| work_keys_str_mv | AT arturomacarronpalacios revolutionizinginvivotherapywithcrisprcasgenomeeditingbreakthroughsopportunitiesandchallenges AT patrickkorus revolutionizinginvivotherapywithcrisprcasgenomeeditingbreakthroughsopportunitiesandchallenges AT bodogcwilkens revolutionizinginvivotherapywithcrisprcasgenomeeditingbreakthroughsopportunitiesandchallenges AT najmehheshmatpour revolutionizinginvivotherapywithcrisprcasgenomeeditingbreakthroughsopportunitiesandchallenges AT saritarpatnaik revolutionizinginvivotherapywithcrisprcasgenomeeditingbreakthroughsopportunitiesandchallenges |